港股異動丨CXO板塊集體重挫,藥明生物跌超9%,特朗普敦促藥廠返美生產,否則面臨關税
港股市場CXO板塊集體重挫,其中,藥明生物、藥明康德跌超9%,維亞生物跌超8%,方達控股、康龍化成、泰格醫藥跌超6%。有媒體引述消息人士稱,美國總統特朗普在一次非公開會議上警吿藥廠關税即將到來,稱企業應儘快將海外生產轉移到美國。特朗普上週在白宮會見多間製藥企業的高層,包括禮來、默克、輝瑞的行政總裁,以及業內最大遊説組織的負責人。這些藥廠高層原本希望説服特朗普支持縮減一項允許聯邦政府對某些藥品價格進行談判的法律,並支持遏制中間商的政策。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.